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Breast carcinoma is one of the most common malignancies in
women worldwide. Human breast tissue is a target for oestrogens.
Oestrogens have an important role to play in the development of
hormone-dependent breast carcinomas (Thomas, 1984; Vihko and
Apter, 1989), and oestrogen receptor (ER) status is well-known to
affect the prognosis of patients with breast neoplasms (Rose et al,
1983). 17b-hydroxysteroid dehydrogenase (17b-HSD) catalyses
the reversible interconversion of oestrogens. Recently, isozymes
of 17b-HSD have been cloned, and it has been demonstrated 
that 17b reduction and oxidation of oestrogens are catalysed 
by different 17b-HSD isozymes. 17b-HSD type 1 catalyses the
conversion of inactive oestrogen, oestrone (E1), to biologically
active oestrogen, oestradiol (E2) (Peltoketo et al, 1988; Luu-The et
al, 1989; Gast et al, 1989), while 17b-HSD type 2 catalyses the
conversion of E2 to E1 (Wu et al, 1993). 17b-HSD type 1 and type
2 regulate the tissue level of E2 and modulate oestrogenic actions
in oestrogen target tissues. Therefore, examining the expression of
17b-HSD type 1 and type 2 in human breast carcinoma is critical
in obtaining a better understanding of the local regulation of
oestrogenic actions in human breast carcinoma.
Recently, immunohistochemical studies of 17b-HSD type 1 have
been reported in human breast carcinoma by Poutanen et al (1992a)
and Sasano et al (1996). However, the number of patients examined
was relatively limited in these reports, and the relationship to 
clinicopathological parameters and the biological significance of
17b-HSD type 1 are still unclear. In addition, little is known about
17b-HSD type 2 in human breast carcinoma. Therefore, in this
study, we immunohistochemically examined the expression of 17b-
HSD type 1 and type 2 in 111 human breast carcinomas, and corre-
lated these findings with various clinicopathological parameters, in
order to study the local regulatory mechanisms of oestrogens in
human breast carcinoma.
MATERIALS AND METHODS
Patients and tissues
A total of 111 specimens of invasive ductal carcinoma of the breast
were obtained from female patients who underwent mastectomy
from 1984 to 1989 at the Department of Surgery, Tohoku
University Hospital, Sendai, Japan. The mean age was 52 years
(range 27–82). All the patients examined had not received irradia-
tion or chemotherapy prior to surgery. The clinical data, including
patient age, menopausal status, stage according to UICC TNM
classification (1987), tumour size and lymph node status, were
retrieved from patient charts. The histological grade in each
specimen was evaluated by three of the authors (TS, TM and NA),
based on the modified method of Bloom and Richardson (1957)
according to Elston and Ellis (1991). The mean follow-up time
was 110 months (range 13–157). Disease-free survival data were
available for all patients.
All specimens were routinely processed (10% formalin-fixed
and paraffin-embedded) at the Department of Pathology, Tohoku
University Hospital, Sendai, Japan.
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Antibodies
The characteristics of the primary antibodies employed in this
study are summarized in Table 1. 17b-HSD type 1 antibody was a
rabbit polyclonal antibody against the enzyme purified from
human placenta (Poutanen et al, 1992a), and was kindly provided
by Dr Poutanen, University of Oulu, Oulu, Finland. The mono-
clonal antibody (mAb) of 17b-HSD type 2, mAb-C2-12, was
produced by immunizing mice with a synthetic carboxyl-terminal
peptide corresponding to amino acids 375–387 of 17b-HSD type 2
(Moghrabi et al, 1997), and was kindly provided by Dr Andersson,
University of Texas Southwestern Medical Center, Dallas, TX,
USA. Utilization of these antibodies for immunohistochemistry
has been previously reported (Takeyama et al, 1998). Monoclonal
antibodies for ER (ER1D5), progesterone receptor (PR; MAB429)
and Ki-67 (MIB1) were purchased from Immunotech (Marseille,
France), Chemicon (Temecula, CA, USA) and Immunotech
(Marseille, France) respectively.
Immunohistochemistry
Immunohistochemical analyses were performed employing the
streptavidin–biotin amplification method using a Histofine Kit
(Nichirei, Tokyo, Japan), and have been previously described in
detail (Suzuki et al, 1994). The antigen–antibody complex was
visualized with 3.3¢-diaminobenzidine (DAB) solution (1 mM
DAB, 50 mM Tris–HCl buffer (pH 7.6), and 0.006% hydrogen
peroxide (H2O2)), and counterstained with methyl green. Tissue
sections of full-term placenta were used as positive controls for
17b-HSD type 1 and type 2 (Takeyama et al, 1998). Endometrial
tissue from the secretory phase was used as a positive control for
17b-HSD type 2 (Casey et al, 1994). As a negative control, normal
rabbit or mouse IgG was used instead of the primary antibodies.
No specific immunoreactivity was detected in these sections.
Double immunostaining
Double immunohistochemical staining for 17b-HSD type 1 and
ER was performed as previously reported (Suzuki et al, 1998).
Briefly, deparaffinized sections were treated with 1% normal goat
serum for 20 min, and incubated with primary antibody for 
17b-HSD type 1 (dilution; 1/800) for 18 h at 4°C. The slides were
then treated with alkaline phosphatase coupled anti-mouse IgG
(Histofine Kit; Nichirei, Tokyo, Japan), and visualized by Vector
blue (Vector Laboratories, Burlingame, CA, USA) in 0.1 M
Tris–HCl buffer, pH 8.2. After pretreatment, which involved the
heating of slides in an autoclave at 120°C for 5 min in citric acid
buffer (2 mM citric acid and 9 mM trisodium citrate dehydrate, 
pH 6.0), the slides were placed in 0.3% H2O2 in methanol for 
15 min, treated with 1% normal goat serum for 20 min at room
temperature, and incubated with anti-ER (dilution; 1/1) for 18 h at
4°C. The slides were subsequently reacted with Envision (Dako,
Copenhagen, Denmark), then visualized with DAB. Haematoxylin
was used for counterstaining. As a negative control, sections were
incubated with normal rabbit or mouse IgG instead of the primary
antibodies. No specific immunoreactivity was detected in these
sections.
Scoring of immunoreactivity
All of the immunolabelled cells were evaluated as positive, regard-
less of the immuno-intensity. For statistical analyses of 
17b-HSD immunoreactivity, we determined the percentage of
positive cells in each carcinoma, according to the study by Sasano
et al (1996), with some modification. After completely reviewing
the immunostained sections of each carcinoma, three of the
authors (TS, TM and NA) independently divided the carcinomas
into the following three groups: ++, more than 50% positive cells;
+, 0–50% positive cells; and –, no immunoreactivity. Cases with
disconcordant results among the observers were re-evaluated.
Scoring of ER, PR and Ki-67 in carcinoma cells was performed on
high power fields (´400) using a standard light microscope. In
each case, more than 500 carcinoma cells were counted indepen-
dently by these same four authors, and the percentage of
immunoreactivity, i.e. labelling index (LI), was determined. In the
present study, inter-observer differences were less than 5%, and
the mean of the three values was obtained.
Statistical analysis
Values for patient age, tumour size and LIs of ER, PR and Ki-67
were presented as mean ± 95% confidence interval (95% CI).
Association between 17b-HSD immunoreactivity and these para-
meters were evaluated using a Bonferroni test. We also evaluated
the statistical differences between patients for 17b-HSD
immunoreactivity and menopausal status, stage, lymph node
status, or histological grade in a cross-table using the c2 test. 
P-values less than 0.05 were considered as significant. Overall and
disease-free survival analyses were calculated according to the
Kaplan–Meier test. The statistical significance of the differences
in the survival analyses was calculated using the log-rank test.
RESULTS
Immunohistochemistry
17b-HSD type 1 immunoreactive protein was detected in the cyto-
plasm of carcinoma cells (Figure 1 A,B), and the relative
Table 1 Characteristics of primary antibodies employed in the present study
Antibody Source Pretreatment Dilution
17b-HSD type 1 (polyclonal) Poutanen et al., 1992a None 1/800
17b-HSD type 2 (monoclonal) Moghrabi et al., 1997 Autoclavea 1/10
ER (monoclonal) Immunotech (Marseille, France) Autoclavea 1/2
PR (monoclonal) Chemicon (Temecula, CA, USA) Autoclavea 1/30
Ki-67 (monoclonal) Immunotech (Marseille, France) Autoclavea 1/50
aHeat in an autoclave for 5 min in citric acid buffer (2 mM citric acid and 9 mM trisodium citrate dehydrate, pH 6.0).immunointensity was heterogeneous among the cases. In this
study, the number of cases in each group according to 17b-HSD
type 1 expression was as follows: ++, n = 30 (27.0%); +, n = 38
(34.2%); and –, n = 43 (38.7%). Immunoreactivity for 17b-HSD
type 2 was absent in all cases of breast carcinoma examined;
however, it was detected in the vascular endothelium of the
placenta and in the glandular epithelium of the endometrium
during the secretory phase, as reported previously (Takeyama et al,
1998; Casey et al, 1994). Immunoreactivity for ER and PR was
observed in the nuclei of carcinoma cells, and that of Ki-67 was
detected in the nuclei of carcinoma cells, as well as some stromal
cells.
Correlation between 17b-HSD type 1 and
clinicopathological parameters
The results of correlation between 17b-HSD type 1 and clinico-
pathological parameters are summarized in Table 2. Of the 111
invasive ductal carcinomas examined in the present investigation,
a significant inverse correlation was detected between 17b-HSD
type 1 immunoreactivity and histological grade of the carcinoma
tissue (P < 0.02). There was, however, no significant correlation
between 17b-HSD type 1 immunoreactivity and patient age,
menopausal status, stage, tumour size, or lymph node status in this
study.
Correlation between 17b-HSD type 1 and steroid
receptors or Ki-67
There was a significant correlation between 17b-HSD type 1
immunoreactivity and ER LI (P < 0.05; ++ (52.4 ± 10.9) vs – (33.4
± 11.6)) (Figure 2A). Upon analysing double immunohistochem-
ical results, 17b-HSD type 1-positive carcinoma cells were
frequently positive for ER simultaneously (Figure 3 A,B). A signif-
icant correlation was also detected between 17b-HSD type 1
immunoreactivity and PR LI (P < 0.05; ++ (57.7 ± 13.0) vs – (37.9
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Figure 1 Immunohistochemistry for 17b-HSD type 1 in invasive ductal carcinoma. (A) 17b-HSD type 1 immunoreactivity was observed in carcinoma cells. 
(B) Negative control for 17b-HSD type 1 shows no specific immunoreactivity in the same field. Original magnification ´230, bar = 50 mm respectively
Table 2 Correlation between 17b-HSD type 1 immunoreactivity and clinicopathological parameters in human
breast carcinomas
17b-HSD type 1 immunoreactivity P-value
++ (n = 30) + (n = 38) – (n = 43)
Agea (years) 53.3 ± 5.1 54.6 ± 3.6 49.2 ± 3.5 NS
Menopausal status
Premenopausal 19 (17.1%) 13 (11.7%) 24 (21.6%)
Post-menopausal 11 (9.9%) 25 (22.5%) 19 (17.1%) NS
Stage
I 9 (8.2%) 11 (10.0%) 11 (10.0%)
II 18 (16.4%) 19 (17.1%) 28 (25.5%)
III 2 (1.8%) 5 (4.5%) 3 (2.7%)
IV 1 (0.9%) 3 (2.7%) 1 (0.9%) NS
Tumour size* (cm) 2.58 ± 0.62 2.57 ± 0.66 2.66 ± 0.33 NS
Lymph node status
n: – 15 (13.5%) 20 (18.0%) 23 (20.7%)
n: + 15 (13.5%) 18 (16.2%) 20 (18.0%) NS
Histological grade
I 13 (11.7%) 9 (8.1%) 6 (5.4%)
II 10 (9.0%) 16 (14.4%) 13 (11.7%)
III 7 (6.3%) 13 (11.7%) 24 (21.6%) <0.02
Data for age and tumour size (a) are presented as mean ± 95% confidence interval (95% CI). All other values
represent the number of cases and percentage.± 11.3)) (Figure 2B). In this study, there was a linear relationship
between ER and PR LIs (r = 0.529, P < 0.0001) when the calcula-
tion of Pearson’s rank correlation coefficient was utilized.
There was also a significant inverse correlation between 17b-HSD
type 1 immunoreactivity and Ki-67 LI (P < 0.0001; ++ (20.1 ± 4.6)
vs – (36.8 ± 5.8), P < 0.01; + (25.2 ± 4.3) vs –) (Figure 2C).
Correlation between 17b-HSD type 1 and prognosis
No significant correlation was detected between 17b-HSD type 1
immunoreactivity and overall or disease-free survival in the 111
invasive ductal carcinomas investigated in this study.
DISCUSSION
It is well recognized that oestrogens contribute immensely to the
development of hormone-dependent breast carcinomas (Thomas,
1984; Vihko and Apter, 1989). Previous investigations have
demonstrated that tissue concentrations of E2 in breast carcinomas
were more than ten times higher than those in plasma (Miller et al,
1982; Miller, 1991). However, no consistent evidence of increased
serum oestrogen concentrations or other systemic oestrogen abnor-
malities have been observed in women with breast carcinoma
(James et al, 1981). Enzymatic activities of P450 aromatase, which
converts C19 steroid into E1 (Miller et al, 1982; Bulun and
Simpson, 1994), and 17b-HSD (Pollow et al, 1977; Bonney et al,
1983) have been reported in breast carcinomas. In addition, P450
aromatase immunolocalization has been demonstrated in stromal
cells of breast carcinoma tissues (Sasano et al, 1994). In this study,
immunoreactivity for 17b-HSD type 1 was detected in carcinoma
cells in 68 out of 111 invasive ductal carcinoma cases (61.3%),
regardless of patient age. The frequency and localization of
immunoreactive 17b-HSD type 1 are consistent with previous
reports (Poutanen et al, 1992a; Sasano et al, 1996). These data all
indicate that biologically active oestrogen E2 is synthesized from
androgen precursors in situ in human breast carcinoma. In this
study, immunoreactivity for 17b-HSD type 2 was absent in all
cases of breast carcinoma, although the immunoreactivity was
17b-HSD in breast carcinoma 521
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Figure 2 Correlation between immunohistochemical expression of 17b-
HSD type 1 and ER LI (A), PR LI (B), or Ki-67 LI (C). (A) There was a
significant correlation between 17b-HSD type 1 immunoreactivity and ER LI
(P < 0.05; ++ (52.4 ± 10.9) vs – (33.4 ± 11.6)). (B) A significant correlation
was observed between 17b-HSD type 1 immunoreactivity and PR LI
(P < 0.05; ++ (57.7 ± 13.0) vs – (37.9 ± 11.3)). (C) There was a significant
inverse correlation between 17b-HSD type 1 immunoreactivity and Ki-67 LI
(P < 0.0001; ++ (20.1 ± 4.6) vs – (36.8 ± 5.8), P < 0.01; + (25.2 ± 4.3) vs –).
Data are presented as mean ± 95% confidence interval (95% CI)present in positive controls. Therefore, results of the present study
suggest that 17b-HSD type 1 is mainly responsible for regulating
the process leading to the accumulation of E2 in human breast
cancer tissues. Recently, Miettinen et al (1996) reported that some
breast cancer cell lines (BT-20 and MDA-MB-361) expressed
17b-HSD type 2, as well as type 1, and suggested a possible
involvement of 17b-HSD type 2 in the local metabolism of oestro-
gens in some breast carcinomas. This discrepancy may be partly
due to the heterogeneity of carcinoma cells or a difference between
breast carcinoma tissues and cultured carcinoma cells.
In order to obtain a better understanding of the local regulation
of E2 in human breast carcinoma, it is very important to examine
the relationship between 17b-HSD type 1 and ER. Although no
positive correlations have been reported previously (Fournier et al,
1985; Leszczynski et al, 1988; Sasano et al, 1996), in this study,
however, a significant correlation between 17b-HSD type 1
immunoreactivity and ER LI (P < 0.05) was observed. In addition,
co-expression of 17b-HSD type 1 and ER was frequently detected
in carcinoma cells as shown in double immunohistochemical
analysis. 17b-HSD type 1 immunoreactivity is suggested to reflect
its enzymatic activity (Poutanen et al, 1992a), and ER immuno-
reactivity correlates closely with oestrogen-dependent biological
phenomena (Marrazzo et al, 1989). Therefore, our present data
suggest that E2, synthesized by 17b-HSD type 1 in carcinoma
cells, acts on these cells locally in invasive ductal carcinomas. A
significant correlation between 17b-HSD type 1 immunoreactivity
and PR LI (P < 0.05) was also detected in this study, which is also
consistent with a study previously reported by Poutanen et al
(1992a). This may be partly due to the fact that the expression of
PR is oestrogen-regulated (Rosen, 1996). ER-positive carcinomas
are generally PR-positive (Rosen, 1996), and therefore it is not
surprising to observe a strong correlation between ER and PR LIs
(r = 0.529, P < 0.0001) in this study. On the other hand, it has also
been demonstrated that the expression of 17b-HSD was induced
by progestin in T-47D (Poutanen et al, 1990, 1992b) and MCF-7
(Adams et al, 1988) human breast cancer cells. Therefore, co-
expression of 17b-HSD type 1 and PR may be consistent, in part,
with the regulation of 17b-HSD type 1 by progesterone.
There was a significant inverse correlation between 17b-HSD
type 1 immunoreactivity and Ki-67 LI (P < 0.0001) or histological
grade (P < 0.02) in this study. Antibody Ki-67 has been shown to
recognize cells in all phases of the cell cycle except the G0
(resting) phase (Gerdes et al, 1983), and it has been studied in a
variety of normal and neoplastic human tissues (Brown and Gatter,
1990). In addition to histological grade (Elston and Ellis, 1991),
Ki-67 LI is also well-known to be a useful prognostic factor in
human breast carcinoma (Veronese et al, 1993). Inverse correla-
tions between these factors and ER LI (Reiner et al, 1988;
Veronese and Gambacorta, 1991) have been reported. Our present
data are consistent with these previous reports, and it is suggested
that breast carcinomas positive for 17b-HSD type 1 are relatively
well differentiated and maintain some of the normal hormonal
regulatory mechanisms that lead to a low proliferation rate.
However, 17b-HSD type 1-negative carcinomas may be less
differentiated and escape these controls, possibly regulating in an
enhanced replicating capacity.
In summary, we demonstrated 17b-HSD type 1 immunoreac-
tivity in invasive ductal carcinomas, but immunoreactivity of 17b-
HSD type 2 was not detected in any of the cases examined.
Immunoreactivity for 17b-HSD type 1 was significantly correlated
with both ER and PR LIs, and inversely correlated with both Ki-67
LI and histological grade. Our present data suggest that 17b-HSD
type 1 plays an important role in the regulation of in situ E2
production and actions in hormone-dependent breast carcinomas.
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